Routine immunization services in Africa: back to basics
Journal Title: Journal of Vaccines & Immunization - Year 2013, Vol 1, Issue 1
Abstract
National immunization programmes were created as a sequel to smallpox eradication when countries undertook mass immunization campaigns and other control measures to fight the disease. As smallpox came near to eradication, the World Health Organization took advantage of the expertise of the smallpox programme and created the Expanded Programme on Immunization. Six vaccines were to be delivered to all children of eligible age through routine immunization services. Despite the recent excellent results in immunizing children in the region, Africa is in danger of failing to reach the Millennium Development Goals (MDGs). There are funding shortfalls and a sapping of political will that are preventing progress towards attaining the health components of the MDGs in Africa. Recognizing these realities, in December 2011, the Task Force for Immunization in Africa encouraged countries to refocus on delivering basic immunization services, the original mandate for routine immunization services. There is no single solution to raising routine coverage in all African countries. Challenges such as the scarcity of resources will test countries to the utmost. All partners in immunization believe that African children deserve the protection afforded by vaccines. And to make the best use of available vaccines requires a renewed emphasis and prioritization of routine immunization services in African countries - the platform on which other immunization activities can be mounted.
Authors and Affiliations
Nshimirimana D, Mihigo R, Clements CJ
Keywords
Related Articles
- EP ID EP566992
- DOI 10.14312/2053-1273.2013-2
- Views 58
- Downloads 0
Comparison of the live attenuated mumps vaccine (Miyahara strain) with its preattenuated parental strain
Live attenuated mumps vaccines have been developed by passaging the field isolates in cells that differ from the natural host. To study mumps viral (MuV) attenuation at the genomic level, we compared a live attenuated mu...
Immunogenicity of 13-valent pneumococcal conjugate vaccine in immunocompetent older adults with stable underlying medical conditions
The 13-valent pneumococcal conjugate vaccine (PCV13) elicits robust functional antibody responses in immunocompetent adults aged ≥50 years, including healthy adults and those considered at risk (ie, stable, chronic cardi...
Developing a vaccine for human rhinoviruses
Rhinoviruses (RV’s) are common human pathogens of the respiratory tract being the most frequent cause of mild diseases of the upper respiratory tract (common cold) but more importantly they are a major initiator of acute...
Home-based vaccination records and hypothetical cost-savings due to avoidance of re-vaccinating children
As national immunization programmes, particularly those in low- and middle-income countries where administrative recording of services received is often absent or sub-optimal, enter a period of rapidly paced change with...
From package to protection: how do we close global coverage gaps to optimize the impact of vaccination?
The success of every vaccination program is dependent upon reaching and sustaining the target coverage rates. Vaccination programs are currently facing coverage gaps where target coverages are never reached and may also...